A molecule made by our own bodies, called Itaconate, can suppress key events that promote asthma by targeting an important immune protein called JAK1, reveals the latest research by a team of scientists at School of Biochemistry and Immunology at Trinity Biomedical Sciences Institute (TBSI).  The research project, led by Dr Luke O’Neill, a professor of Biochemistry, found that blocking JAK1 has shown remarkable efficacy in lab-based models of severe asthma. The findings, published in Cell, indicated the possibility of medicines based on Itaconate having potential as a new therapeutic approach to treat asthma.